ALLR Stock Price, Allarity Therapeutics, . Quote, Chart

Market Summary

USD0.64-0.03

Market Closed

-4.48%

ALLR Stock Price

View Fullscreen

ALLR RSI Chart

ALLR Valuation

Market Cap

1.5M

Price/Earnings (Trailing)

-0.12

EV/EBITDA

-0.11

Price/Free Cashflow

-0.14

MarketCap/EBT

-0.13

ALLR Price/Earnings (Trailing)

ALLR Profitability

Return on Equity

192.07%

Return on Assets

-103.84%

Free Cashflow Yield

-722.3%

ALLR Fundamentals

ALLR Earnings

Earnings (TTM)

-12.4M

Earnings Growth (Yr)

-15.75%

Earnings Growth (Qtr)

-125.32%

Breaking Down ALLR Revenue

Last 7 days

-19.0%

Last 30 days

-57.3%

Last 90 days

-92.1%

Trailing 12 Months

-99.7%

How does ALLR drawdown profile look like?

ALLR Financial Health

Current Ratio

0.13

Debt/Equity

-0.13

Debt/Cashflow

-13.58

ALLR Investor Care

Shares Dilution (1Y)

28734.83%

Diluted EPS (TTM)

1.4K

Which funds bought or sold ALLR recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 15, 2024	TWO SIGMA SECURITIES, LLC	sold off	-100	-20,694	-	-%
May 15, 2024	Tower Research Capital LLC (TRC)	added	3.32	-1,329	1,722	-%
May 15, 2024	MORGAN STANLEY	new	-	2.00	2.00	-%
May 13, 2024	UBS Group AG	new	-	9,941	9,941	-%
May 10, 2024	WELLS FARGO & COMPANY/MN	added	12.5	-7.00	11.00	-%
May 01, 2024	CONCOURSE FINANCIAL GROUP SECURITIES, INC.	sold off	-	-	-	-%
May 01, 2024	CONCOURSE FINANCIAL GROUP SECURITIES, INC.	sold off	-	-	-	-%
Feb 26, 2024	Virtu Financial LLC	reduced	-41.83	-11,000	8,000	-%

Are Funds Buying or Selling ALLR?

Are funds buying ALLR calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own ALLR

No. of Funds

Unveiling Allarity Therapeutics, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 12, 2024	3i, lp	9.9%	653,377	SC 13G/A

Recent SEC filings of Allarity Therapeutics, Inc.

View All Filings

Date Filed	Form Type	Document
May 17, 2024	424B5	Prospectus Filed
May 15, 2024	424B5	Prospectus Filed
May 15, 2024	8-K	Current Report
May 14, 2024	10-Q	Quarterly Report
May 09, 2024	424B5	Prospectus Filed
May 09, 2024	8-K	Current Report
May 08, 2024	RW	RW
May 06, 2024	424B5	Prospectus Filed
May 06, 2024	8-K	Current Report
May 03, 2024	8-K	Current Report

Allarity Therapeutics, Inc. News

Latest updates

Allarity Therapeutics, Inc. Earnings Report: Key Takeaways & Analysis

Balance Sheet

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Balance Sheet															(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2019Q4
Assets	0.9%	11,969	11,862	13,875	13,426	12,702	14,544	18,134	23,231	31,290	49,633	36,987	38,780	36,092	33,403	31,607
Current Assets	16.4%	2,295	1,971	4,387	3,686	2,966	4,968	6,061	10,119	17,211	21,404	7,635	8,497	-	1,715	3,343
Cash Equivalents	88.0%	312	166	1,399	351	295	2,029	3,946	7,677	14,544	19,555	5,584	6,598	105	298	1,524
Net PPE	-10.0%	18.00	20.00	29.00	26.00	25.00	21.00	5.00	5.00	6.00	8.00	9.00	10.00	-	21.00	37.00
Liabilities	26.2%	18,440	14,613	17,254	14,149	13,041	12,654	14,631	13,149	14,416	30,849	7,326	9,960	9,462	8,964	10,704
Current Liabilities	27.1%	18,008	14,167	15,744	12,668	11,588	11,222	12,955	11,462	12,711	20,719	3,838	4,335	-	5,533	4,719
Long Term Debt	-	-	-	-	-	-	-	-	812	-	785	773	-	-	737	-
LT Debt, Current	-	-	-	-	-	2,687	2,644	-	-	-	-	-	-	-	1,327	-
Shareholder's Equity	-135.2%	-6,471	-2,751	-	-	-3,102	-113	1,447	7,966	14,732	18,152	29,661	28,823	23,468	24,439	20,035
Retained Earnings	-4.1%	-98,294	-94,451	-92,729	-88,282	-85,902	-82,550	-79,712	-74,675	-69,572	-66,492	-49,676	-45,090	-	-39,844	-32,374
Additional Paid-In Capital	0.4%	90,699	90,369	88,366	82,588	83,437	83,158	83,029	83,868	84,233	85,243	78,948	67,933	-	62,482	50,623
Shares Outstanding	16.5%	343	294	209	25.00	-	567.80*	328.35*	6.00	296.01*	289.14*	276.89*	179.19*	161.91*	151.86*	-
Float	-	-	-	-	3,324	-	-	-	10,593	-	-	-	-	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																	(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2019Q4
Cashflow From Operations	11.1%	-1,487	-1,672	-5,376	-2,496	-3,201	-2,446	-4,408	-4,208	-5,755	-4,319	-3,734	-4,266	-2,567	-2,439	-905	-	-
Share Based Compensation	52.4%	-121	-254	124	180	-121	340	406	-59.00	1,065	5,163	577	433	195	-12.00	236	-	-
Cashflow From Investing	-	-	-	-	-	-	-18.00	-	-	809	5.00	-	-	-	-	-	-	-
Cashflow From Financing	164.4%	1,380	522	6,450	2,865	1,158	1,000	-	-	-	18,437	2,346	10,710	2,325	2,700	1,314	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

ALLR Income Statement

2024-03-31

Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Operating expenses:
Research and development	$ 2,170	$ 1,427
General and administrative	2,070	2,241
Total operating expenses	4,240	3,668
Loss from operations	(4,240)	(3,668)
Other income (expenses)
Interest income		4
Interest expense	(102)	(92)
Foreign exchange gains	76	95
Change in fair value adjustment of derivative and warrant liabilities	419	309
Net other income	393	316
Net loss for the period before tax benefit	(3,847)	(3,352)
Income tax benefit	4
Net loss	(3,843)	(3,352)
Deemed dividend of 5% on Series C Convertible Preferred stock		(4)
Gain on extinguishment of Series A Convertible Preferred stock	191
Deemed dividend on Series A Convertible Preferred stock	(228)
Net loss attributable to common stockholders	$ (3,880)	$ (3,356)
Basic net loss per common stock (in Dollars per share)	$ (22.14)	$ (6,356.06)
Weighted-average number of common stock outstanding, Basic (in Shares)	175,266	528
Other comprehensive loss, net of tax:
Net loss	$ (3,843)	$ (3,352)
Change in cumulative translation adjustment	25	84
Total comprehensive loss attributable to common stockholders	$ (3,818)	$ (3,268)

ALLR Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash	$ 312	$ 166
Other current assets	110	209
Prepaid expenses	542	781
Tax credit receivable	1,331	815
Total current assets	2,295	1,971
Non-current assets:
Property, plant and equipment, net	18	20
Intangible assets	9,656	9,871
Total assets	11,969	11,862
Current liabilities:
Accounts payable	11,058	8,416
Accrued liabilities	1,553	1,309
Warrant derivative liability	2,664	3,083
Income taxes payable	43	59
Convertible promissory notes and accrued interest, net of debt discount	2,690	1,300
Total current liabilities	18,008	14,167
Non-current liabilities:
Deferred tax	432	446
Total liabilities	18,440	14,613
Commitments and contingencies (Note 16)
Stockholders’ (deficit) equity
Series A Preferred stock $0.0001 par value (20,000 shares designated) shares issued and outstanding at March 31, 2024 and December 31, 2023 were 1,215 and 1,417, respectively (liquidation preference of $4.36 at March 31, 2024)	1,510	1,742
Common stock, $0.0001 par value (750,000,000 shares authorized, at March 31, 2024 and December 31, 2023); shares issued and outstanding at March 31, 2024 and December 31, 2023 were 342,774 and 294,347, respectively
Additional paid-in capital	90,699	90,369
Accumulated other comprehensive loss	(386)	(411)
Accumulated deficit	(98,294)	(94,451)
Total stockholders’ deficit	(6,471)	(2,751)
Total liabilities, preferred stock and stockholders’ (deficit) equity	$ 11,969	$ 11,862

About Allarity Therapeutics, Inc.

Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA (ixabepilone), a selective microtubule inhibitor in phase 2 for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. The company has a collaboration with Detsamma Investments Pty. Ltd. to develop Deflexifol for the treatment of solid tumors. Allarity Therapeutics, Inc. was incorporated in 2004 and is headquartered in Boston, Massachusetts.

0

CEO	Mr. James G. Cullem J.D.
WEBSITE	allarity.com
INDUSTRY	Biotechnology

Allarity Therapeutics, Inc. Frequently Asked Questions

What is the ticker symbol for Allarity Therapeutics, Inc.? What does ALLR stand for in stocks?

ALLR is the stock ticker symbol of Allarity Therapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Allarity Therapeutics, Inc. (ALLR)?

As of Fri May 17 2024, market cap of Allarity Therapeutics, Inc. is 1.53 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ALLR stock?

You can check ALLR's fair value in chart for subscribers.

What is the fair value of ALLR stock?

You can check ALLR's fair value in chart for subscribers. The fair value of Allarity Therapeutics, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Allarity Therapeutics, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ALLR so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Allarity Therapeutics, Inc. a good stock to buy?

The fair value guage provides a quick view whether ALLR is over valued or under valued. Whether Allarity Therapeutics, Inc. is cheap or expensive depends on the assumptions which impact Allarity Therapeutics, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ALLR.